### DESCRIPTION

**Species Reactivity**
Human/Mouse

**Specificity**
Detects human DR3/TNFRSF25 in direct ELISAs and Western blots. Shows 100% cross-reactivity with recombinant mouse (rm) DR3/TNFRSF25 and no cross-reactivity with recombinant human (rh) 4-1BB, rhCD27, rhCD30, rhCD40, rhDR6, rhBAFF R, rhFas, rhGITR, rhLTRβ, rhNGF R, rhOPG, rmOX40, rhRANK, rhTAJ, rhTNF RI, rhTNF RIi, or rhHVEM.

**Source**
Monoclonal Mouse IgG1 Clone # 59204

**Purification**
Protein A or G purified from ascites

**Immunogen**
Mouse myeloma cell line NS0-derived recombinant human DR3 isoform 1 Gln25-Phe201

**Accession #**
Q93038

**Conjugate**
Allophycocyanin

**Excitation Wavelength:** 620-650 nm

**Emission Wavelength:** 660-670 nm

**Formulation**
Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.

*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.*

### APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

#### Flow Cytometry

<table>
<thead>
<tr>
<th>Recommended Concentration</th>
<th>Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 µL/10⁶ cells</td>
<td>See Below</td>
</tr>
</tbody>
</table>

**DATA**

**Flow Cytometry**
Detection of DR3/TNFRSF25 in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) either (A) untreated or (B) treated with PMA and Calcium Ionomycin for 24 hours were stained with Mouse Anti-Human/Mouse DR3/TNFRSF25 APC-conjugated Monoclonal Antibody (Catalog # FAB943A) and Mouse Anti-Human CD3ε PE-conjugated Monoclonal Antibody (Catalog # FAB100P). Quadrant markers were set based on control antibody staining (Catalog # IC002A). View our protocol for Staining Membrane-associated Proteins.

**Flow Cytometry**
Detection of DR3/TNFRSF25 in Mouse Splenocytes by Flow Cytometry. Mouse splenocytes either (A) untreated or (B) treated with PMA and Calcium Ionomycin for 24 hours were stained with Mouse Anti-Human/Mouse DR3/TNFRSF25 APC-conjugated Monoclonal Antibody (Catalog # FAB943A) and Rat Anti-Mouse CD3ε PE-conjugated Monoclonal Antibody (Catalog # FAB4841P). Quadrant markers were set based on control antibody staining (Catalog # IC002A). View our protocol for Staining Membrane-associated Proteins.

### PREPARATION AND STORAGE

**Shipping**
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage**
Protect from light. Do not freeze.

- 12 months from date of receipt, 2 to 8 °C as supplied.
Death receptor 3 (DR3), also known as lymphocyte-associated receptor of death (LARD), WSL-1, APO3, TRAMP and TR3, is a glycoprotein belonging to the TNF receptor superfamily (TNFRSF) (1-5). DR3 was formerly designated TNFRSF12 when it was thought to be a receptor for TWEAK/TNFSF12 (6). However, work disavowed the DR3:TWEAK interaction and DR3 is now designated TNFRSF25 (7). By alternative splicing, at least 11 distinct human DR3 transcripts encoding secreted or type I membrane proteins exist (7). The human DR3 isoform 1 cDNA encodes a 417 amino acid residue (aa) transmembrane precursor with a 24 aa signal peptide, a 175 aa extracellular domain containing four cysteine-rich repeats and two potential N-glycosylation sites, a 21 aa transmembrane region and a 195 aa cytoplasmic region with one death domain. DR3 is one of six within the TNF R superfamily that contains a death domain in its cytoplasmic region. It is most closely related to TNF R1 and FAS/CD95, sharing 29% and 23% aa sequence identity, respectively. DR3 is expressed primarily in tissues enriched in lymphocytes. Whereas naïve B and T cells express multiple truncated DR3 isoforms but not the transmembrane isoform 1, upon T cell activation, expression of the transmembrane DR3 isoform 1 predominates. TL1A/VEGI, a TNF superfamily ligand, has been shown to bind and activate DR3 (8). Depending on the cell context, ligation of DR3 by TL1A can trigger one of two signaling pathways. On primary T cells, TL1A induces NF-kappa-B activation and a costimulatory signal to increase IL-2 responsiveness and the secretion of proinflammatory cytokines. However, in a tumor cell line, TF-1, TL1A has been shown to induce caspase activity and apoptosis. In DR3-null mice, an impairment of negative selection and anti-CD3-mediated thymocyte apoptosis is observed.

References: